Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new...

Full description

Saved in:
Bibliographic Details
Published in:New England Journal of Medicine 2021-12
Main Authors: Pilishvili, Tamara, Gierke, Ryan, Fleming-Dutra, Katherine E, Farrar, Jennifer L, Mohr, Nicholas M, Talan, David A, Krishnadasan, Anusha, Harland, Karisa K, Smithline, Howard A, Hou, Peter C, Lee, Lilly C, Lim, Stephen C, Moran, Gregory J, Krebs, Elizabeth, Steele, Mark T, Beiser, David G, Faine, Brett, Haran, John P, Nandi, Utsav, Schrading, Walter A, Chinnock, Brian, Henning, Daniel J, Lovecchio, Frank, Lee, Jane, Barter, Devra, Brackney, Monica, Fridkin, Scott K, Marceaux-Galli, Kaytlynn, Lim, Sarah, Phipps, Erin C, Dumyati, Ghinwa, Pierce, Rebecca, Markus, Tiffanie M, Anderson, Deverick J, Debes, Amanda K, Lin, Michael Y, Mayer, Jeanmarie, Kwon, Jennie H, Safdar, Nasia, Fischer, Marc, Singleton, Rosalyn, Chea, Nora, Magill, Shelley S, Verani, Jennifer R, Schrag, Stephanie J
Format: Article
Language:English
Subjects:
COVID-19 vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting. Methods We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose). Results The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (
DOI:10.1056/NEJMoa2106599